EGFR and glioblastoma: Focal deletion of 9p21.3 harboring cyclin-dependent kinase Inhibitor 2A (CDKN2A) is associated (p < 0.01, two sided Student’s t test) with classical GBM, which co-occurs with EGFR amplification in 94% cases [18].